Gareth Morgan
@DrGarethMorgan1
Followers
4K
Following
923
Media
290
Statuses
2K
Clinician and researcher; committed to improving outcomes of myeloma, amyloid and Waldenstrom's.
NYU Langone, Manhattan, NYC
Joined April 2019
Really interesting observation that needs further exploration.
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis #lymphoidneoplasia
2
0
2
Well done Bea great work.
Research Brief: Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
0
1
3
I think this is really cool art to go with this article well done bcd for adding to the science.
Now online: Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
2
1
10
RT @iannisaifantis1: more than excited to welcome @JohnPLeonardMD in our @nyugrossman Family. and for his plan to strengthen heme blood ca….
0
3
0
Very good read.
🧬 Proud to share: Publication in Blood Cancer Journal: .Activity of CAR-T cells and bispecific antibodies in multiple myeloma with EMD. 👉CAR T-cell therapy and effective debulking resulted in higher EMD response rates, and prolonged PFS. 👉
3
0
9
RT @JohnPLeonardMD: We’re proud to share that @nyulangone is ranked #16 in the U.S. for Cancer by @usnews! It’s a testament to our integrat….
0
9
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Case series of elranatamab for relapsed &/or refractory advanced stage AL #amyloidosis finds 10….
0
17
0
Super work from two excellent NYU resident @nyulangone.
Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma - ScienceDirect
0
0
3
Super work from two NYU residents #nyu #NYULangone.
Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma - ScienceDirect
0
0
4
Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma - ScienceDirect
1
1
7
RT @MAstronomers: 🚨: A 9,000-year-old skeleton in Somerset was genetically matched to a local man named Adrian Targett. Their mitochondrial….
0
4K
0
Long-term outcomes of light chain amyloidosis patients receiving heart transplant: A single-center experience - PubMed
pubmed.ncbi.nlm.nih.gov
Select AL patients with advanced cardiac involvement can gain survival advantage with OHT similar to other advanced heart failure patients.
0
0
9
RT @nyulangone: Welcoming Dr. John P. Leonard as chief of the Division of Hematology & Medical Oncology and director of the Center for Bloo….
0
9
0
RT @DKThomp: Yes. Writing is not a second thing that happens after thinking. The act of writing is an act of thinking. Writing *is* think….
0
7K
0
RT @iannisaifantis1: Good to see some good press from @TheEconomist on the impact of cancer basic+clinical research. #CancerResearch #Canc….
0
4
0
GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma | GSK - interesting twist!
gsk.com
The US FDA Oncologic Drugs Advisory Committee voted against the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations.
1
1
7
RT @Ron_Witteles: Another disappointment for #AL #amyloidosis #depleters: CARES didn’t meet its primary endpoint. What exactly was the pres….
reuters.com
AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, the...
0
11
0